Register Login

Exelixis Inc (EXEL)

(90% Positive) Exelixis Inc (EXEL) Announces Enrollment Update for results Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:54 p.m.

    📋 Exelixis Inc (EXEL) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:22:36

    Event Type: Clinical Trial Update

    Event Details:

    Exelixis Inc (EXEL) Announces Clinical Trial Update Exelixis Inc (EXEL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, billion
    • Diseases/Conditions: preliminary U
    • Updated Timeline: fiscal year 2025, Fiscal Year 2025
      • expected in mid-2026
      • targeting ADC), XB628 (PD-L1 + NKG2A bispecific) and XB371 (TF-targeting ADC). If phase 1 data are supportive, Exelixis plans to progress these molecules into full development as part of its strategy to build next-generation oncology franchises across tumor types and novel combination regimens, including with zanzalintinib and other therapeutic modalities. Combination opportunities of particular development interest highlighted at the December 2025
      • planned for release after market on Tuesday, February 10, 2026

    🔬 Clinical Development Pipeline (Exelixis Inc):

    Product Type Development Stage Therapeutic Area Source
    Atezolizumab DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    XB371 DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    XL309 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Cabozantinib DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    XB010 DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumors ClinicalTrials.gov
    Belzutifan DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE2 Castration-resistant Prostate Cancer ClinicalTrials.gov
    XB628 BIOLOGICAL Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Everolimus DRUG Phase PHASE2 Pancreatic Neuroendocrine Tumor (pNET) ClinicalTrials.gov
    Zanzalintinib DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    Questionnaire Administration OTHER Phase PHASE1 Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation ClinicalTrials.gov
    Quality-of-Life Assessment OTHER Phase PHASE1 Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation ClinicalTrials.gov
    Enfortumab Vedotin DRUG Phase PHASE1 Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation ClinicalTrials.gov
    Cabozantinib S-malate DRUG Phase PHASE1 Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation ClinicalTrials.gov
    Pembrolizumab BIOLOGICAL Phase PHASE2 Metastatic Head and Neck Carcinoma ClinicalTrials.gov
    XL092 DRUG Phase PHASE2 Advanced Renal Cell Carcinoma ClinicalTrials.gov
    Nivolumab + Relatlimab DRUG Phase PHASE1 Renal Cell Carcinoma (RCC) ClinicalTrials.gov
    Ipilimumab DRUG Phase PHASE1 Renal Cell Carcinoma (RCC) ClinicalTrials.gov
    erlotinib DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    XL184 DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Sunitinib Malate DRUG Phase PHASE2 Malignant Neoplasms of Urinary Tract ClinicalTrials.gov
    prednisone DRUG Phase PHASE2 Prostate Cancer ClinicalTrials.gov
    abiraterone DRUG Phase PHASE2 Prostate Cancer ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Enzalutamide DRUG Phase PHASE3 Metastatic Prostate Cancer ClinicalTrials.gov
    Abiraterone Acetate DRUG Phase PHASE3 Metastatic Prostate Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Uterine Cancer ClinicalTrials.gov
    Sorafenib DRUG Phase PHASE3 Hepatocellular Carcinoma ClinicalTrials.gov
    Cobimetinib DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Vemurafenib DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    XL888 DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Cetuximab DRUG Phase PHASE1 Head and Neck Neoplasms ClinicalTrials.gov
    Tissue biopsy PROCEDURE Phase PHASE2 High Grade Neuroendocrine Neoplasms ClinicalTrials.gov
    Blood for plasma biomarkers PROCEDURE Phase PHASE2 High Grade Neuroendocrine Neoplasms ClinicalTrials.gov
    Etoposide Capsule DRUG Phase PHASE1 Germ Cell Tumor ClinicalTrials.gov
    Stereotactic Radiosurgery (SRS) RADIATION Phase PHASE1 Metastatic Renal Cell Carcinoma ClinicalTrials.gov
    Durvalumab DRUG Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Tremelimumab DRUG Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Regorafenib DRUG Phase PHASE3 Colorectal Cancer ClinicalTrials.gov
    Cabozantinib 80 MG DRUG Phase PHASE2 RCC ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Differentiated Thyroid Cancer ClinicalTrials.gov
    XL844 DRUG Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    XL820 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    XL418 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    rosiglitazone DRUG Phase PHASE1 Papillary Thyroid Cancer ClinicalTrials.gov
    XL019 DRUG Phase PHASE1 Myeloproliferative Disorders ClinicalTrials.gov
    famotidine DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    XL281 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    temozolomide DRUG Phase PHASE1 Glioblastoma ClinicalTrials.gov
    Radiation Therapy RADIATION Phase PHASE1 Glioblastoma ClinicalTrials.gov
    XL228 DRUG Phase PHASE1 Chronic Myeloid Leukemia ClinicalTrials.gov
    XL147 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    XL647 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    cabozantinib tablets DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    cabozantinib capsules DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    mitoxantrone DRUG Phase PHASE3 Prostate Cancer ClinicalTrials.gov
    Cabozantinib (XL184) DRUG Phase PHASE1 Relapsed or Refractory Multiple Myeloma ClinicalTrials.gov
    Laboratory Biomarker Analysis OTHER Phase PHASE2 Poorly Differentiated Thyroid Gland Carcinoma ClinicalTrials.gov
    Erlotinib 100Mg Tab DRUG Phase PHASE2 Pancreatic Adenocarcinoma Metastatic ClinicalTrials.gov
    Cabozantinib 40 MG DRUG Phase PHASE2 Pancreatic Adenocarcinoma Metastatic ClinicalTrials.gov
    Usability of an electronic symptom management application DEVICE Approved Metastatic Renal Cell Carcinoma Treated With Cabozantinib ClinicalTrials.gov
    Everolimus (Afinitor) tablets DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    Trastuzumab DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Panitumumab BIOLOGICAL Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Placebo tablets DRUG Phase PHASE3 Hepatocellular Carcinoma ClinicalTrials.gov
    Pembrolizumab 200 mg IV every 3 weeks DRUG Phase PHASE2 Cervical Cancer ClinicalTrials.gov
    Cabozantinib 40 MG oral once a day DRUG Phase PHASE2 Cervical Cancer ClinicalTrials.gov
    Radical Prostatectomy PROCEDURE Phase PHASE2 Prostate Cancer ClinicalTrials.gov
    Androgen Ablation Therapy DRUG Phase PHASE2 Prostate Cancer ClinicalTrials.gov
    XL114 DRUG Phase PHASE1 Non-Hodgkin's Lymphoma (NHL) ClinicalTrials.gov
    Afatinib DRUG Phase PHASE2 Non-small Cell Lung Carcinoma ClinicalTrials.gov
    Fulvestrant DRUG Phase PHASE1 Neoplasm Malignant ClinicalTrials.gov
    XL102 DRUG Phase PHASE1 Neoplasm Malignant ClinicalTrials.gov
    Cytoreductive nephrectomy PROCEDURE Phase PHASE2 Kidney Cancer ClinicalTrials.gov
    Cystectomy PROCEDURE Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Bevacizumab DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    XB002 DRUG Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    ADC cytotoxic agents DRUG Phase PHASE1 Solid Cancers ClinicalTrials.gov
    XL495 DRUG Phase PHASE1 Solid Cancers ClinicalTrials.gov
    Computerized tomography (CT) Scan PROCEDURE Phase PHASE2 Clear Cell Renal Cell Cancer (ccRCC) ClinicalTrials.gov
    Bone Scan PROCEDURE Phase PHASE2 Clear Cell Renal Cell Cancer (ccRCC) ClinicalTrials.gov
    Non-Investigational Radiation Therapy (RT) RADIATION Phase PHASE2 Clear Cell Renal Cell Cancer (ccRCC) ClinicalTrials.gov
    Investigator Choice of Bone Strengthening Agents (BSA) DRUG Phase PHASE2 Clear Cell Renal Cell Cancer (ccRCC) ClinicalTrials.gov
    Avelumab DRUG Phase PHASE1 Neoplasm Malignant ClinicalTrials.gov
    Cabozantinib-matched placebo DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    Eribulin DRUG Phase PHASE1 Advanced Leiomyosarcoma ClinicalTrials.gov
    AB521 DRUG Phase PHASE1 Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors ClinicalTrials.gov
    Lu-177 DRUG Phase PHASE1 Neuroendocrine Tumors ClinicalTrials.gov
    Transarterial Chemoembolization PROCEDURE Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Placebo capsule DRUG Phase PHASE4 Medullary Thyroid Cancer ClinicalTrials.gov
    Placebo tablet DRUG Phase PHASE4 Medullary Thyroid Cancer ClinicalTrials.gov
    Cabozantinib (XL184) 60 mg DRUG Phase PHASE4 Medullary Thyroid Cancer ClinicalTrials.gov
    Cabozantinib (XL184) 140 mg DRUG Phase PHASE4 Medullary Thyroid Cancer ClinicalTrials.gov
    Zanzalintinib-matched Placebo DRUG Phase PHASE2 Head and Neck Squamous Cell Carcinoma ClinicalTrials.gov
    Olaparib DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    13-cis-retinoic acid DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Exelixis Inc
    • Ticker Symbol: EXEL

Search

News categories